Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Unlock the Power of Synapse: A Guide to Searching Dexamethasone
Drug Insights
2 min read
Unlock the Power of Synapse: A Guide to Searching Dexamethasone
9 February 2024
Dexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging.
Read →
Sandoz Launches Tyruko®, a Unique Biosimilar for Multiple Sclerosis Treatment, in Germany
Latest Hotspot
3 min read
Sandoz Launches Tyruko®, a Unique Biosimilar for Multiple Sclerosis Treatment, in Germany
9 February 2024
Sandoz introduces Tyruko® (natalizumab), a first-of-its-kind biosimilar aimed at treating multiple sclerosis, now available in Germany.
Read →
How to Effectively Search for Furosemide on Synapse
Drug Insights
2 min read
How to Effectively Search for Furosemide on Synapse
9 February 2024
Furosemide is a small molecule NKCC2 inhibitor drug, blocking the sodium-potassium-chloride co-transporter in the kidney's ascending loop of Henle.
Read →
J&J Seeks FDA Approval for DARZALEX FASPRO in Treating Newly Diagnosed Multiple Myeloma Cases
Latest Hotspot
4 min read
J&J Seeks FDA Approval for DARZALEX FASPRO in Treating Newly Diagnosed Multiple Myeloma Cases
9 February 2024
Johnson & Johnson has filed an additional request with the FDA for authorization of its DARZALEX FASPRO formula as a therapy option for newly identified multiple myeloma cases eligible for transplant.
Read →
Your Ultimate Guide to Finding Clonazepam on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Clonazepam on Synapse
9 February 2024
KLONOPIN (clonazepam) is a benzodiazepine medication that was first approved by the FDA in 1975 for the treatment of seizure disorders and panic disorder.
Read →
US and Japan Approve BMS's Breyanzi Filings for Recurrent Lymphomas
Latest Hotspot
3 min read
US and Japan Approve BMS's Breyanzi Filings for Recurrent Lymphomas
9 February 2024
U.S. and Japanese authorities have approved filings for Bristol Myers Squibb's Breyanzi, aimed at treating recurrent Follicular and Mantle Cell Lymphomas.
Read →
Explore Sildenafil on Synapse: Tips and Tricks for Better Search Results
Drug Insights
2 min read
Explore Sildenafil on Synapse: Tips and Tricks for Better Search Results
9 February 2024
Viagra relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.
Read →
Vertex Announces Promising Phase 3 Results of VX-548 for Acute Pain Management
Latest Hotspot
4 min read
Vertex Announces Promising Phase 3 Results of VX-548 for Acute Pain Management
9 February 2024
Vertex Reveals Encouraging Outcomes from Phase 3 Trials of VX-548 for Moderate to Intense Short-Term Pain Management.
Read →
Strategically Search Citalopram on Synapse: A How-to Guide
Drug Insights
2 min read
Strategically Search Citalopram on Synapse: A How-to Guide
9 February 2024
Citalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines.
Read →
FDA Approves CellVax's FK-PC101 IND Submission for Personalized Cancer Immunotherapy
Latest Hotspot
3 min read
FDA Approves CellVax's FK-PC101 IND Submission for Personalized Cancer Immunotherapy
9 February 2024
CellVax Therapeutics has received approval from the FDA for its IND submission for FK-PC101, a new individualized immunotherapy treatment for cancer.
Read →
User-friendly Guide to Find Clonidine on Synapse
Drug Insights
2 min read
User-friendly Guide to Find Clonidine on Synapse
9 February 2024
Clonidine lowers blood pressure by stimulating α2 receptors in the brain, which results in relaxation of many arteries.
Read →
DP Tech Unveils Kv1.3 Blocker Candidate for IBD and AD Treatment
Latest Hotspot
3 min read
DP Tech Unveils Kv1.3 Blocker Candidate for IBD and AD Treatment
9 February 2024
DP Tech has revealed its selection of a developmental contender, a promising top-tier Kv1.3 blocker aimed at tackling immune disorders like IBD and AD.
Read →